AbbVie Raises 2025 Guidance and Eyes Strategic Deals in Neuroscience, Obesity, and Oncology

AbbVie raised its full-year 2025 adjusted diluted EPS guidance from $11.67-$11.87 to $11.88-$12.08, despite a $0.55 per share hit from acquired R&D and milestones recorded through Q2 20251.

Full-year 2025 revenue guidance was increased by $800 million, now targeting $60.5 billion3.

Q2 2025 results exceeded expectations, with EPS at $2.97 (versus $2.96 forecast) and revenue at $15.4 billion (surpassing $14.99 billion expected)3.

Major product growth drivers included strong sales from SKYRIZI and RINVOQ in immunology and neuroscience3.

AbbVie is pursuing dealmaking efforts in key therapeutic areas, specifically targeting assets in neuroscience, obesity, and PD-1/VEGF oncology combinations, aiming to bolster its pipeline beyond current core products13.

The stock price rose 4.76% in pre-market trading after the earnings and guidance boost, reflecting increased investor confidence3.

Sources:

1. https://www.prnewswire.com/news-releases/abbvie-reports-second-quarter-2025-financial-results-302518052.html

3. https://www.investing.com/news/transcripts/earnings-call-transcript-abbvie-q2-2025-sees-stock-surge-on-earnings-beat-93CH-4164055